Patient acceptable symptom state and minimally clinically important difference for patient-reported outcomes in systemic sclerosis: A secondary analysis of the sclereduc trial
Camille Daste(Inserm), Christelle Nguyen(Délégation Paris 5), Luc Mouthon(Université Paris Cité), É. Hachulla(Centre Hospitalier Universitaire de Lille), Serge Poiraudeau(Institut Régional de Médecine Physique et de Réadaptation), V. Tiffreau(Université de Lille), Emmanuel Chatelus(Laboratoire National de Référence), Jean Sibilia(Immunologie, Immunopathologie et Chimie Thérapeutique), François Rannou(Délégation Paris 5), Katherine Sanchez(Délégation Paris 5), J. Cabané(Sorbonne Université), P. Thoumie(Université Paris Cité), Alexandra Rören(Délégation Paris 5)
Cited by 0
Related Papers
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
|New England Journal of Medicine|2009|857
Mapping and predicting mortality from systemic sclerosis
|Annals of the Rheumatic Diseases|2017|699
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456